AMGN trades near $465, up 4.7% on the week, roughly in line with the median gain of 4.1% across its closest large-cap biotech peers. GILD and VRTX ran harder, adding 9.4% and 6.7% respectively, while BIIB lagged at 1.2%. Within that context, Amgen's move looks measured rather than stretched. Options positioning has flipped notably toward…
AMGN cost to borrow surges to 0.59%, up 216% over the past week, signaling tightening lending conditions despite low short interest at 2.4% of float.
Key data as of 4 Nov 2026
AMGN cost to borrow surges to 0.59%, up 216% over the past week, signaling tightening lending conditions despite low short interest at 2.4% of float.
AMGN trades near $465, up 4.7% on the week, roughly in line with the median gain of 4.1% across its closest large-cap biotech peers. GILD and VRTX ran harder, adding 9.4% and 6.7% respectively, while BIIB lagged at…
Options traders are rotating out of puts on AMGN at the sharpest pace in months. The put-call ratio fell to 0.96 on Monday, 2.45 standard deviations below its 20-day mean of 1.07, the most bullish reading in the recent…
Amgen reports Q1 results on May 19 with options positioning flashing the most defensive signal in months — even as short sellers quietly reduce their bets. The standout heading into the print is in options. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AMGN — free to start on ORTEX.
Sign up for free →Open AMGN on ORTEX